Proterris, Inc.

Proterris, Inc. is a privately held, clinical-stage biotechnology company headquartered in Boston, Massachusetts, that describes itself as "The Carbon Monoxide Therapeutics Company." The company is focused on developing carbon monoxide (CO)-based therapies, using precision science and clinical research to improve patient outcomes in critical care and inflammatory diseases. Its lead programs target complications in solid organ transplantation, an area where CO's cytoprotective, anti-inflammatory, and anti-fibrotic properties are being investigated. Proterris was co-founded by Apeiron Partners together with a consortium of leading academic and medical institutions, including the University of Pittsburgh, Columbia University, Beth Israel Deaconess Medical Center, Johns Hopkins, and Yale University. The company states that it holds a strong global intellectual property position and is initially concentrating on the therapeutic use of CO to improve outcomes in solid organ transplantation. The company's pipeline includes PRO-301, aimed at preventing delayed graft function (DGF) in kidney transplant, and PRO-302, aimed at preventing primary graft dysfunction (PGD) in lung transplant. Proterris is also developing small-molecule CO releasers, extending its platform beyond inhaled CO therapies. Its research spans transplant, kidney, and inflammatory disease areas. Proterris is led by a management team with deep life-science and biotechnology experience. Co-founder Jeff Wager, MD, serves as Executive Chairman and has been a senior executive, serial entrepreneur, and investor in the life sciences for over 30 years. Co-founder Augustine M.K. Choi, MD, serves as Chief Scientific Officer. Kourosh Saeb-Parsy serves as Chief Medical Officer, Richard Boyer, MD, PhD, as Chief Technology Officer, and Stefan W. Ryter, Ph.D., as Senior Scientist. The board of directors includes Jeff Wager, Peter Hutt, Don DeBethizy, Ph.D., and Peter Fernandes. Co-founders and advisors include Alex Stenzler and David Pinsky, MD. As a private, development-stage company, Proterris does not disclose public financial results. Its activities center on advancing its CO therapeutic programs through preclinical and clinical research, with the goal of addressing significant unmet needs in transplantation and critical care.

Proterris, Inc. is a Boston-based biotechnology company focused on carbon monoxide (CO) therapeutics. It was co-founded by Apeiron Partners and a consortium of leading institutions, including the University of Pittsburgh, Columbia University, Beth Israel Deaconess Medical Center, Johns Hopkins, and Yale University. The company was established to translate decades of preclinical research on CO as a therapeutic gasotransmitter into clinical therapies, initially for solid organ transplantation. CO has been increasingly recognized for its cytoprotective, anti-inflammatory, and anti-fibrotic properties. Among therapeutic gasotransmitters, it stands out for its extensive preclinical validation across multiple disease areas, with beneficial effects observed at doses well below known toxicity thresholds. Proterris built its platform around this science, developing a portfolio of inhaled and small-molecule CO therapies. The company's lead programs are PRO-301, targeting delayed graft function (DGF) prevention in kidney transplant, and PRO-302, targeting primary graft dysfunction (PGD) prevention in lung transplant. It is also developing small-molecule CO releasers. Proterris states that it holds a strong global intellectual property position. Proterris is led by co-founder Jeff Wager, MD, as Executive Chairman, and co-founder Augustine M.K. Choi, MD, as Chief Scientific Officer. The management team also includes Kourosh Saeb-Parsy as Chief Medical Officer, Richard Boyer, MD, PhD, as Chief Technology Officer, and Stefan W. Ryter, Ph.D., as Senior Scientist. The board includes Jeff Wager, Peter Hutt, Don DeBethizy, Ph.D., and Peter Fernandes. Co-founders and advisors include Alex Stenzler and David Pinsky, MD. As a private, clinical-stage company, Proterris does not disclose detailed financial or operational history publicly. Its development efforts remain focused on advancing its CO therapeutic candidates through preclinical and clinical research.

Clinical-stage biotechnology company developing carbon monoxide-based therapeutics for transplantation, critical care, and inflammatory diseases.

• PRO-301

  Therapeutic candidate for DGF prevention in kidney transplant.

• PRO-302

  Therapeutic candidate for PGD prevention in lung transplant.

• Small Molecule CO Releasers

  Small-molecule carbon monoxide releasing compounds.

1. 1Proterris - Homeproterris.com
2. 2Proterris - Aboutproterris.com
3. 3Proterris, Inc. (United States) - Wikidatawikidata.org